BioMimetic Continues Trying for Augment Approval

Brentwood-based BioMimetic has filed yet another round of paperwork in hopes of gaining federal approval for its bone graft therapy, called Augment.

The company first submitted its only product to the Food and Drug Administration more than two years ago; earlier this year, while still waiting to be able to sell Augment in the US, nearly a quarter of the company’s staff were laid off. With the latest filing, BioMimetic officials say they’re hoping for an FDA verdict sometime next year.

Please keep your community civil. Comments will be moderated prior to posting, and Nashville Public Radio reserves the right to approve them at its discretion. Comments containing links promoting goods, services - even noble organizations - will not be published. Your comments may include external links, but all comments with links will be delayed as they are reviewed. Comments containing profanity will be rejected.